Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Accounts Payables (2016 - 2025)

Ascendis Pharma A's Accounts Payables history spans 6 years, with the latest figure at $101.7 million for Q4 2023.

  • For Q4 2023, Accounts Payables fell 1.29% year-over-year to $101.7 million; the TTM value through Dec 2023 reached $101.7 million, down 1.29%, while the annual FY2023 figure was $102.3 million, 3.93% down from the prior year.
  • Accounts Payables for Q4 2023 was $101.7 million at Ascendis Pharma A, down from $103.1 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $103.1 million in Q4 2022 and bottomed at $26.1 million in Q4 2020.
  • The 3-year median for Accounts Payables is $101.7 million (2023), against an average of $77.0 million.
  • The largest YoY upside for Accounts Payables was 1.29% in 2023 against a maximum downside of 1.29% in 2023.
  • A 3-year view of Accounts Payables shows it stood at $26.1 million in 2020, then surged by 294.82% to $103.1 million in 2022, then fell by 1.29% to $101.7 million in 2023.
  • Per Business Quant, the three most recent readings for ASND's Accounts Payables are $101.7 million (Q4 2023), $103.1 million (Q4 2022), and $26.1 million (Q4 2020).